4-EA-NBOMe: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
{{Short description|A synthetic psychedelic compound}}
{{DISPLAYTITLE:4-EA-NBOMe}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477318123
| IUPAC_name = 2-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
| image = 4-EA-NBOMe_Structure.svg
}}


'''4-EA-NBOMe''' is a synthetic psychedelic compound that belongs to the [[NBOMe]] class of drugs. It is a derivative of the phenethylamine 2C-E and is known for its potent hallucinogenic effects.
== 4-EA-NBOMe ==


==Chemical Structure==
[[File:4-EA-NBOMe_Structure.svg|thumb|right|Chemical structure of 4-EA-NBOMe]]
4-EA-NBOMe is chemically related to the 2C family of phenethylamines, specifically 2C-E. The compound is characterized by the presence of a 4-ethyl group on the phenyl ring and a methoxybenzyl group attached to the nitrogen atom. This structural modification is responsible for its high affinity for the [[serotonin receptor|5-HT2A receptor]], which is believed to mediate its psychedelic effects.


==Pharmacology==
'''4-EA-NBOMe''' is a synthetic psychedelic compound belonging to the [[NBOMe]] class. It is a derivative of the phenethylamine 4-ethylanisole and is known for its potent hallucinogenic effects. The compound is structurally related to other NBOMe substances, which are known for their high affinity for the [[serotonin receptor|5-HT2A receptor]].
4-EA-NBOMe acts primarily as a potent agonist of the [[5-HT2A receptor]], a subtype of the serotonin receptor. This interaction is thought to be the primary mechanism through which it exerts its psychedelic effects. The compound may also interact with other serotonin receptor subtypes, contributing to its overall pharmacological profile.


==Effects==
== Chemical Properties ==
The effects of 4-EA-NBOMe are similar to those of other NBOMe compounds and include visual and auditory hallucinations, altered perception of time and space, and changes in mood and thought processes. The intensity and duration of these effects can vary depending on the dose and individual sensitivity.


==Safety and Toxicity==
4-EA-NBOMe is characterized by the presence of a methoxybenzyl group attached to the nitrogen atom of the phenethylamine backbone. This modification is responsible for its increased potency compared to its parent compound, 4-ethylanisole. The chemical structure of 4-EA-NBOMe can be represented by the formula C<sub>18</sub>H<sub>23</sub>NO<sub>3</sub>.
The safety profile of 4-EA-NBOMe is not well-established, and its use is associated with significant risks. Like other NBOMe compounds, it has been linked to severe adverse effects, including [[vasoconstriction]], [[hypertension]], [[tachycardia]], and [[seizures]]. Due to its potency and potential for harm, it is considered a dangerous substance.


==Legal Status==
== Pharmacology ==
The legal status of 4-EA-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use.


==Related pages==
4-EA-NBOMe acts primarily as a partial agonist at the [[5-HT2A receptor]], which is the primary target for classical psychedelics such as [[LSD]] and [[psilocybin]]. The activation of this receptor is believed to be responsible for the psychedelic effects experienced by users. The compound may also interact with other serotonin receptors, contributing to its overall pharmacological profile.
* [[NBOMe series]]
 
* [[2C family]]
== Effects ==
 
The effects of 4-EA-NBOMe are similar to those of other NBOMe compounds and include visual hallucinations, altered perception of time, and changes in mood and thought processes. The onset of effects typically occurs within 30 to 90 minutes after administration, with the peak effects lasting for several hours. Users may experience both positive and negative effects, including euphoria, introspection, anxiety, and confusion.
 
== Safety and Toxicity ==
 
The safety profile of 4-EA-NBOMe is not well-established, and there is limited information on its toxicity in humans. As with other NBOMe compounds, there is a risk of overdose, which can lead to severe adverse effects such as [[vasoconstriction]], [[hypertension]], [[tachycardia]], and [[seizures]]. Due to these risks, the use of 4-EA-NBOMe is discouraged outside of controlled research settings.
 
== Legal Status ==
 
The legal status of 4-EA-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other banned NBOMe compounds. Users should be aware of the legal implications of possessing or distributing this substance in their region.
 
== Related Pages ==
 
* [[NBOMe]]
* [[Psychedelic drug]]
* [[Psychedelic drug]]
* [[Serotonin receptor]]
* [[Serotonin receptor]]
 
* [[Phenethylamine]]
==Gallery==
<gallery>
File:4-EA-NBOMe_Structure.svg|Chemical structure of 4-EA-NBOMe
</gallery>


[[Category:Psychedelic phenethylamines]]
[[Category:Psychedelic phenethylamines]]
[[Category:Serotonin receptor agonists]]
[[Category:Serotonin receptor agonists]]

Latest revision as of 11:32, 15 February 2025


4-EA-NBOMe[edit]

Chemical structure of 4-EA-NBOMe

4-EA-NBOMe is a synthetic psychedelic compound belonging to the NBOMe class. It is a derivative of the phenethylamine 4-ethylanisole and is known for its potent hallucinogenic effects. The compound is structurally related to other NBOMe substances, which are known for their high affinity for the 5-HT2A receptor.

Chemical Properties[edit]

4-EA-NBOMe is characterized by the presence of a methoxybenzyl group attached to the nitrogen atom of the phenethylamine backbone. This modification is responsible for its increased potency compared to its parent compound, 4-ethylanisole. The chemical structure of 4-EA-NBOMe can be represented by the formula C18H23NO3.

Pharmacology[edit]

4-EA-NBOMe acts primarily as a partial agonist at the 5-HT2A receptor, which is the primary target for classical psychedelics such as LSD and psilocybin. The activation of this receptor is believed to be responsible for the psychedelic effects experienced by users. The compound may also interact with other serotonin receptors, contributing to its overall pharmacological profile.

Effects[edit]

The effects of 4-EA-NBOMe are similar to those of other NBOMe compounds and include visual hallucinations, altered perception of time, and changes in mood and thought processes. The onset of effects typically occurs within 30 to 90 minutes after administration, with the peak effects lasting for several hours. Users may experience both positive and negative effects, including euphoria, introspection, anxiety, and confusion.

Safety and Toxicity[edit]

The safety profile of 4-EA-NBOMe is not well-established, and there is limited information on its toxicity in humans. As with other NBOMe compounds, there is a risk of overdose, which can lead to severe adverse effects such as vasoconstriction, hypertension, tachycardia, and seizures. Due to these risks, the use of 4-EA-NBOMe is discouraged outside of controlled research settings.

Legal Status[edit]

The legal status of 4-EA-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other banned NBOMe compounds. Users should be aware of the legal implications of possessing or distributing this substance in their region.

Related Pages[edit]